TY - JOUR T1 - No impact of smoking status on breast cancer tumor infiltrating lymphocytes, response to neoadjuvant chemotherapy and prognosis JF - medRxiv DO - 10.1101/2020.06.05.20123273 SP - 2020.06.05.20123273 AU - Vanille Simon AU - Lucie Laot AU - Enora Laas AU - Sonia Rozette AU - Julien Guerin AU - Thomas Balezeau AU - Marion Nicolas AU - Jean-Yves Pierga AU - Florence Coussy AU - Marick LaƩ AU - Diane de Croze AU - Beatriz Grandal AU - Judith Abecassis AU - Fabien Reyal AU - Anne-Sophie Hamy Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123273.abstract N2 - INTRODUCTION Tobacco use is associated with an increase in breast cancer (BC) mortality. Pathologic complete response rate to neoadjuvant chemotherapy (NAC) is influenced by tumor-infiltrating lymphocytes (TILs) levels and is associated with a better long-term survival outcome. Whether tobacco modifies either tumoral microenvironment such as TIL levels, either pCR rates remains unclear. The aim of our study is to evaluate the impact of smoking status on TIL levels, response to NAC and prognosis for BC patients.METHODS We retrospectively evaluated pre and post NAC stromal and intra tumoral TIL levels and pCR rates on a cohort of T1-T3NxM0 BC patients treated with NAC between 2002 and 2012 at Institut Curie. Smoking status (current, ever, never smokers) was collected in clinical records. We analyzed the association between smoking status, TIL levels, pCR rates and survival outcomes among the whole population, and after stratification by BC subtype.RESULTS A total of 956 BC patients with available smoking status information were included in our analysis [current smokers, n=179 (18.7%); ever smokers, n=154 (16.1%) and never smokers, n = 623 (65.2%)]. Median pre-NAC TIL levels, pCR rates, or median post-NAC TIL levels were not significantly different according to smoking status, neither in the whole population, nor after stratification by BC subtype. With a median follow-up of 101.4 months, relapse free survival (RFS) and overall survival (OS) were not significantly different by smoking status.CONCLUSION In this study, we did not find any significant effect of tobacco use on pre and post NAC TILs nor response to NAC and. Though our data seem reassuring, BC treatment should still be considered as a window of opportunity to offer BC patients accurate smoking cessation interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialcohort CNIL declaration number 1547270Funding StatementWe thank Roche France for financial support for the construction of the Institut Curie neoadjuvant database (NEOREP). Funding was also obtained from the Site de Recherche Integree en Cancerologie/Institut National du Cancer (Grant No. INCa-DGOS-4654). A-S Hamy-Petit was supported by an ITMO-INSERM-AVIESAN translational cancer research grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Breast Cancer Study Group of Institut Curie and was conducted according to institutional and ethical rules regarding research on tissue specimens and patients. Written informed consent from the patients was not required by French regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary material. ER -